Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 2Phase 3 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1

Conditions

Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Angiogenesis Inhibitors × Clear all
NCT05273814 2022-07-13

Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 1 Unknown
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00093873 2013-05-15

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Amgen

Phase 1 Completed
71 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡